Xiaoqin Chen

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

Yun Wang, Xiaoqin Chen, Qi Liang, Weida Wang et autres

BACKGROUND: Adding daratumumab to initial therapy in randomized controlled trials (RCTs) for newly diagnosed multiple myeloma (MM) enhances deep remission and prolongs progression-free survival (PFS). Given the differences between trial-eligible and real-world patients, and healthcare access variability in developing countries, real-world data …

cn, gb (code pays fourni par la source)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study

Dong Liang, Yurong Yan, Qiaoli Wang, Shenrui Bai et autres

This study aimed to discuss the clinical outcomes of extramedullary multiple myeloma in the era of novel agents, based on the largest dataset regarding extramedullary multiple myeloma in China. This study included 597 patients without extramedullary disease (EMD) (non-EMD), 324 with extramedullary …

cn (code pays fourni par la source)

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study

Dong Liang, Yurong Yan, Shenrui Bai, Weiling Xu et autres

PURPOSE: Previous studies have shown that ≥2% circulating tumor cells (CTCs) in multiple myeloma are associated with a prognosis similar to primary plasma cell leukemia. This study aims to examine this ultra-high-risk patient subset and evaluate their clinical outcomes in a real-world …

cn (code pays fourni par la source)

Author response for "Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study"

Dong Liang, Yurong Yan, Qiaoli Wang, Shenrui Bai et autres

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients

Zhongjun Xia, Hua Wang, Liang Wang, Yue Lu et autres

Bortezomib has significantly increased the response rates in multiple myeloma (MM), but optimal bortezomib-based regimens for initial MM therapy have not yet been defined. We retrospectively compared the outcomes of 128 patients newly diagnosed with symptomatic MM who received either bortezomib combined …

cn (code pays fourni par la source)